From The Source

PBAC’s pricing model for HTAs ‘penalises innovation’

4 minute read

Commonwealth Members Women's Health

By

Harriet Grayson

Pharma giants Bayer and Theramex say current frameworks disincentivise companies from submitting new HRT and MHT products to the PBAC.

Pharma giants Bayer and Theramex say current frameworks disincentivise companies from submitting new HRT and MHT products to the PBAC.

This content is for Health Services Daily subscribers only.
or Join Now.

End of content

No more pages to load

Log In Register ×